Cite
HARVARD Citation
Kleef, R. et al. (n.d.). P08.01 Low-dose checkpoint inhibitors with hyperthermia and IL-2 are safe and effective in stage IV cancer with unfavorable immunological profile (MSIlow, PD-L1 under 1%, TMBlow) – A single-institution experience from 2015 to 2020. Journal for immunotherapy of cancer. pp. A49-A50. [Online].